Physician profile
Chadwick E Gambrell
NPI 1578903118
$2,195.14
in general payments reported to CMS, 2019-2025
31 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $180 · 2021: $372 · 2022: $389 · 2023: $405 · 2024: $308 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $269.31 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $264.67 | 2019-2022 | |
| Novo Nordisk INC | $186.92 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $174.71 | 2021-2025 | |
| Amgen INC. | $144.55 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $130.40 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $129.72 | 2019-2024 | Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $97.77 | 2022-2025 | |
| Axsome Therapeutics, INC. | $91.68 | 2023-2025 | Auvelity |
| Pfizer INC. | $83.10 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $67.37 | 2023-2024 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $65.97 | 2025 | |
| Phathom Pharmaceuticals, INC. | $62.73 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $53.18 | 2022-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $34.70 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $29.64 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.84 | 2022 | |
| Exact Sciences Corporation | $27.07 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $26.93 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $25.55 | 2022-2023 | Quviviq |
| Allergan, INC. | $25.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.86 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.58 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.16 | 2021-2022 | |
| Cequr Corporation | $19.65 | 2024 | Cequr Simplicity |
| Abbott Laboratories | $15.62 | 2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $14.67 | 2020 | |
| Azurity Pharmaceuticals, INC. | $14.57 | 2024 | Edarbi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.11 | 2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $12.61 | 2020 | |
| Bardy Diagnostics, INC. | $10.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadwick Gambrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.